{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:54Z","timestamp":1789471974901,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["MISP ID 59252"],"award-info":[{"award-number":["MISP ID 59252"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA. JIA- and uveitis-related data, including intraocular inflammation, best-corrected visual acuity, corticosteroid-sparing potential, and ocular complications were evaluated at start of GLM treatment, at 1\u2009month and 3\u2009months, and every 3\u2009months thereafter during GLM administration. We further investigated the association of response to GLM with primary and secondary failure of ADA treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ten patients were studied, all female (17 affected eyes, mean age 14.3\u00a0<jats:underline>+<\/jats:underline>\u00a06.7\u2009yrs., mean follow-up 25.2\u00a0<jats:underline>+<\/jats:underline>\u00a021.7 mos). Two patients were switched to GLM because of primary non-response to ADA. Eight were switched because of loss of response (LOR).<\/jats:p>\n                <jats:p>In 5 of the latter LOR was associated with neutralizing anti-ADA-antibodies. Response to GLM was observed in all 8 patients with LOR, while the 2 patients with primary non-response to ADA also did not respond to GLM. Three of the 8 responders experienced LOR. At the end of follow-up 4 of the 5 remaining responders had achieved complete response. One had achieved partial response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>GLM is an efficacious therapeutic option in patients who experience LOR to ADA. Our data indicate that patients without primary response to ADA should be rather switched to a biologic agent with a different mode of action instead of further blocking the TNF-alpha pathway.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-021-00630-1","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T20:03:02Z","timestamp":1629576182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab"],"prefix":"10.1186","volume":"19","author":[{"given":"Sofia","family":"Lanz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7797-3124","authenticated-orcid":false,"given":"Andrea","family":"Skrabl-Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,21]]},"reference":[{"issue":"6","key":"630_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/rheumatology\/kem053","volume":"46","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K, German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology. 2007;46(6):1015\u20139.","journal-title":"Rheumatology"},{"issue":"2","key":"630_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/art.22381","volume":"56","author":"RK Saurenmann","year":"2007","unstructured":"Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007;56(2):647\u201357.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"630_CR3","first-page":"309","volume":"28","author":"K Kotaniemi","year":"2001","unstructured":"Kotaniemi K, Aho K, Kotaniemi A. Uveitis as a cause of visual loss in arthritides and comparable conditions. J Rheumatol. 2001;28(2):309\u201312.","journal-title":"J Rheumatol"},{"issue":"1","key":"630_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semarthrit.2018.11.004","volume":"49","author":"A Heiligenhaus","year":"2019","unstructured":"Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2019;49(1):43\u201355.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"630_CR5","first-page":"1107","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"630_CR6","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637\u201346.","journal-title":"N Engl J Med"},{"issue":"7","key":"630_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","volume":"77","author":"P Quartier","year":"2018","unstructured":"Quartier P, Baptiste A, Despert V, Allain-Launay E, Kon\u00e9-Paut I, Belot A, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003\u201311.","journal-title":"Ann Rheum Dis"},{"key":"630_CR8","doi-asserted-by":"publisher","first-page":"108322","DOI":"10.1016\/j.clim.2019.108322","volume":"211","author":"ES Sen","year":"2020","unstructured":"Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322.","journal-title":"Clin Immunol"},{"issue":"6","key":"630_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res. 2019;71(6):703\u201316.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"630_CR10","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/eye.2009.203","volume":"23","author":"N Dhingra","year":"2009","unstructured":"Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye. 2009;23(9):1868\u201370.","journal-title":"Eye"},{"issue":"9","key":"630_CR11","doi-asserted-by":"publisher","first-page":"1892.e3","DOI":"10.1016\/j.ophtha.2011.05.019","volume":"118","author":"M Cordero-Coma","year":"2011","unstructured":"Cordero-Coma M, Salom D, D\u00edaz-Llopis M, L\u00f3pez-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. 2011;118(9):1892.e3\u20134.","journal-title":"Ophthalmology"},{"issue":"2","key":"630_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3109\/09273948.2013.844265","volume":"22","author":"E Miserocchi","year":"2014","unstructured":"Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22(2):90\u20135.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"630_CR13","first-page":"652","volume":"36","author":"N Palmou-Fontana","year":"2018","unstructured":"Palmou-Fontana N, Calvo-R\u00edo V, Mart\u00edn-Varillas JL, Fern\u00e1ndez-D\u00edaz C, Mesquida M, Ad\u00e1n A, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin Exp Rheumatol. 2018;36(4):652\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"630_CR14","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"3","key":"630_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"630_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","volume":"92","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985 Apr;92(4):467\u201371.","journal-title":"Ophthalmology"},{"issue":"5","key":"630_CR17","first-page":"1146","volume":"34","author":"I Foeldvari","year":"2007","unstructured":"Foeldvari I, Nielsen S, K\u00fcmmerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34(5):1146\u201350.","journal-title":"J Rheumatol"},{"issue":"4","key":"630_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3121\/cmr.4.4.294","volume":"4","author":"KG Ooi","year":"2006","unstructured":"Ooi KG, Galatowicz G, Calder VL, Lightman SL. Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin Med Res. 2006 Dec;4(4):294\u2013309.","journal-title":"Clin Med Res"},{"issue":"3","key":"630_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","volume":"104","author":"A Skrabl-Baumgartner","year":"2019","unstructured":"Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child. 2019;104(3):246\u201350.","journal-title":"Arch Dis Child"},{"issue":"3","key":"630_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3899\/jrheum.160072","volume":"44","author":"FA Aeschlimann","year":"2017","unstructured":"Aeschlimann FA, Angst F, Hofer KD, Cannizzaro Schneider E, Schroeder-Kohler S, Lauener R, et al. Prevalence of anti-infliximab antibodies and their associated co-factors in children with refractory arthritis and\/or uveitis: a retrospective longitudinal cohort study. J Rheumatol. 2017;44(3):334\u201341.","journal-title":"J Rheumatol"},{"issue":"4","key":"630_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299\u2013316.","journal-title":"BioDrugs"},{"key":"630_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03009742.2021.1875040","volume":"2","author":"JE Gehin","year":"2021","unstructured":"Gehin JE, Warren DJ, Syversen SW, Lie E, Sexton J, Loli L, et al. Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. Scand J Rheumatol. 2021;2:1\u201310.","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"630_CR23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/rheumatology\/key406","volume":"58","author":"A Heiligenhaus","year":"2019","unstructured":"Heiligenhaus A, Klotsche J, Tappeiner C, Sengler C, Niewerth M, Liedmann I, et al. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the inception cohort of newly diagnosed patients with juvenile idiopathic arthritis (ICON-JIA) study. Rheumatology. 2019;58(6):975\u201386.","journal-title":"Rheumatology"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00630-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T20:07:31Z","timestamp":1629576451000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00630-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00630-1","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,21]]},"assertion":[{"value":"19 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee (EK 31\u2013301 ex 18\/19).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The institutional review board of the Medical University of Graz approved all study procedures, the study protocol, and the informed-consent form for off-lable treatment with GLM. All patients and\/or parents gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}